178 related articles for article (PubMed ID: 15138159)
1. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
[TBL] [Abstract][Full Text] [Related]
2. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
[TBL] [Abstract][Full Text] [Related]
4. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Mackey JR; Galmarini CM; Graham KA; Joy AA; Delmer A; Dabbagh L; Glubrecht D; Jewell LD; Lai R; Lang T; Hanson J; Young JD; Merle-Béral H; Binet JL; Cass CE; Dumontet C
Blood; 2005 Jan; 105(2):767-74. PubMed ID: 15454483
[TBL] [Abstract][Full Text] [Related]
7. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
10. The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
Leuk Lymphoma; 2013 Aug; 54(8):1840-3. PubMed ID: 23808769
[TBL] [Abstract][Full Text] [Related]
11. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
13. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
14. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
Morales AA; Olsson A; Celsing F; Osterborg A; Jondal M; Osorio LM
Int J Cancer; 2005 Feb; 113(5):730-7. PubMed ID: 15499630
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Silber R; Degar B; Costin D; Newcomb EW; Mani M; Rosenberg CR; Morse L; Drygas JC; Canellakis ZN; Potmesil M
Blood; 1994 Nov; 84(10):3440-6. PubMed ID: 7949099
[TBL] [Abstract][Full Text] [Related]
16. DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Grgurevic S; Montilla-Perez P; Bradbury A; Gilhodes J; Queille S; Pelofy S; Bancaud A; Filleron T; Ysebaert L; Récher C; Laurent G; Fournié JJ; Cazaux C; Quillet-Mary A; Hoffmann JS
Haematologica; 2018 Jun; 103(6):1038-1046. PubMed ID: 29567785
[TBL] [Abstract][Full Text] [Related]
17. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
López-Guerra M; Trigueros-Motos L; Molina-Arcas M; Villamor N; Casado FJ; Montserrat E; Campo E; Colomer D; Pastor-Anglada M
Haematologica; 2008 Dec; 93(12):1843-51. PubMed ID: 18945750
[TBL] [Abstract][Full Text] [Related]
18. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
[TBL] [Abstract][Full Text] [Related]
20. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
